WaveMan
WaveMan · Company
ADPT · Adaptive Biotechnologies Corp
> Search tickers & screens ⌘K
LIVE
← All companies

ADPT Adaptive Biotechnologies (ADPT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001478320
Quote by TradingView
Form 144 · 15
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
160
13F, latest reported quarter
Conversions, 180 days
51
Codes C/M, not in net · $12.8M priced

What the filings say about ADPT

Insiders, 180 days
-$60.4M net sold
11 sellers · 54% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$63.6M
15 notices

Adaptive Biotechnologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Adaptive Biotechnologies Corp insiders sold a net $60.4M of stock across 311 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
RUBINSTEIN JULIE
President and COO
SELL
2026-10-26 SEC
8,503
$220.6K
n/a
Context
  • 82 earlier Form 4 trades (code P or S) here by this insider (82 sales), the last on Oct 23, 2026.
  • The trade is 2.2% of the 381,180 shares held after it.
  • 2 other insiders sold within 30 days.
  • 160 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO RUBINSTEIN JULIE sold about $220.6K of ADPT under a 10b5-1 plan on Oct 26, 2026; 2 other insiders sold within 30 days and 160 funds added in the latest 13F quarter.
RUBINSTEIN JULIE
President and COO
SELL
2026-10-26 SEC
3,378
$88.8K
n/a
Context
  • 82 earlier Form 4 trades (code P or S) here by this insider (82 sales), the last on Oct 23, 2026.
  • The trade is 0.9% of the 377,802 shares held after it.
  • 2 other insiders sold within 30 days.
  • 160 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO RUBINSTEIN JULIE sold about $88.8K of ADPT under a 10b5-1 plan on Oct 26, 2026; 2 other insiders sold within 30 days and 160 funds added in the latest 13F quarter.
RUBINSTEIN JULIE
President and COO
SELL
2026-10-26 SECtraded 2026-10-23
4,500
$110.2K
n/a
Context
  • 80 earlier Form 4 trades (code P or S) here by this insider (80 sales), the last on Oct 22, 2026.
  • The trade is 1.2% of the 385,183 shares held after it.
  • 2 other insiders sold within 30 days.
  • 160 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO RUBINSTEIN JULIE sold about $110.2K of ADPT under a 10b5-1 plan on Oct 23, 2026; 2 other insiders sold within 30 days and 160 funds added in the latest 13F quarter.
RUBINSTEIN JULIE
President and COO
SELL
2026-10-26 SECtraded 2026-10-23
7,381
$186.6K
n/a
Context
  • 80 earlier Form 4 trades (code P or S) here by this insider (80 sales), the last on Oct 22, 2026.
  • The trade is 2.0% of the 377,802 shares held after it.
  • 2 other insiders sold within 30 days.
  • 160 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO RUBINSTEIN JULIE sold about $186.6K of ADPT under a 10b5-1 plan on Oct 23, 2026; 2 other insiders sold within 30 days and 160 funds added in the latest 13F quarter.
RUBINSTEIN JULIE
President and COO
SELL
2026-10-26 SECtraded 2026-10-22
10,181
$248.2K
n/a
Context
  • 78 earlier Form 4 trades (code P or S) here by this insider (78 sales), the last on Oct 21, 2026.
  • The trade is 2.7% of the 379,502 shares held after it.
  • 2 other insiders sold within 30 days.
  • 160 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO RUBINSTEIN JULIE sold about $248.2K of ADPT under a 10b5-1 plan on Oct 22, 2026; 2 other insiders sold within 30 days and 160 funds added in the latest 13F quarter.
311 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 306 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$60.4M over 180 days
-$28.9M over 90 days
below 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
160 funds bought in last quarter
more than 84% of Pharma & Biotech
Revenue
+54.8% year over year
more than 78% of Pharma & Biotech
Margin
-21.5% net margin
more than 58% of Pharma & Biotech
Buybacks
$25.0M repurchased, FY to 2026-06-30
below 59% of Pharma & Biotech
Short interest
9.4% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 62% of Pharma & Biotech
What changed in the last 30 days
Oct 26President and COO RUBINSTEIN JULIE sold $5.6M under a 10b5-1 plan (31 trades, Oct 1 to Oct 26)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 8Chief Commercial Officer, MRD BOBULSKY SUSAN sold $193.3K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Officer SUSAN BOBULSKY filed to sell $192.3K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5Chief People Officer LO FRANCIS sold $757.7K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer JULIE RUBINSTEIN filed to sell $11.0M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ADPT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+68.1%12M
-25%+11%+46%+81%2025-102025-122026-022026-042026-062026-082026-10 2026-08-17 · ROBINS CHAD M sold $8.0M2026-08-18 · ROBINS CHAD M sold $6.8M2026-07-21 · ROBINS HARLAN S sold $6.1M2025-11-21 · BENZENO SHARON sold $5.2M2026-07-02 · ROBINS HARLAN S sold $5.2M2025-11-20 · BENZENO SHARON sold $4.9M2026-07-21 · ROBINS HARLAN S sold $4.7M2026-03-02 · ROBINS CHAD M sold $4.6M2026-03-11 · ROBINS HARLAN S sold $4.3M2026-03-11 · ROBINS CHAD M sold $4.3M2026-07-02 · ROBINS HARLAN S sold $3.3M2026-06-29 · BENZENO SHARON sold $3.3M2025-11-28 · PISKEL KYLE sold $3.2M2026-09-16 · LO FRANCIS sold $3.0M2026-02-27 · ROBINS CHAD M sold $2.9M2026-07-15 · LO FRANCIS sold $2.4M2025-12-01 · ROBINS CHAD M sold $2.4M2026-02-02 · ROBINS CHAD M sold $2.3M2026-01-05 · ROBINS CHAD M sold $1.9M2026-03-11 · ROBINS HARLAN S sold $1.9M2026-03-11 · ROBINS CHAD M sold $1.9M2025-12-15 · LO FRANCIS sold $1.8M2026-08-17 · NEUPERT PETER M sold $1.8M2026-06-15 · ROBINS HARLAN S sold $1.7M2026-03-11 · RUBINSTEIN JULIE sold $1.6M2026-01-12 · LO FRANCIS sold $1.4M2025-11-10 · ROBINS CHAD M sold $1.3M2026-04-06 · ROBINS CHAD M sold $1.2M2026-06-25 · GRIFFIN MICHELLE RENEE sold $1.1M2026-07-02 · LO FRANCIS sold $1.0M2026-08-17 · NEUPERT PETER M sold $1.0M2026-07-01 · LO FRANCIS sold $950.9K2026-03-11 · BENZENO SHARON sold $831.1K2026-03-03 · ROBINS CHAD M sold $785.4K2026-03-03 · GRIFFIN MICHELLE RENEE sold $735.1K2025-11-26 · ROBINS CHAD M sold $703.3K2026-06-04 · LO FRANCIS sold $695.1K2026-02-02 · ROBINS HARLAN S sold $644.8K2026-03-05 · LO FRANCIS sold $574.5K2026-04-08 · ROBINS CHAD M sold $566.0K2026-03-11 · BOBULSKY SUSAN sold $544.4K2026-10-01 · LO FRANCIS sold $534.9K2026-10-06 · SUSAN BOBULSKY filed to sell $192.3K2026-10-01 · JULIE RUBINSTEIN filed to sell $11.0M2026-09-16 · FRANCIS LO filed to sell $3.8M2026-09-15 · SUSAN BOBULSKY filed to sell $29.6K2026-08-26 · KATHERINE E OWEN filed to sell $250.0K2026-08-20 · Harlan Robins filed to sell $10.2M2026-08-19 · Harlan Robins filed to sell $5.5M2026-08-18 · ROBERT M HERSHBERG filed to sell $748.3K2026-08-18 · Harlan Robins filed to sell $6.4M2026-08-18 · Chad Robins filed to sell $6.8M2026-08-17 · PETER NEUPERT filed to sell $3.1M2026-08-17 · Chad Robins filed to sell $8.0M2026-08-17 · Harlan Robins filed to sell $7.5M2026-08-10 · SUSAN BOBULSKY filed to sell $74.8K2026-07-30 · SUSAN BOBULSKY filed to sell $29.3K2026-07-21 · Harlan Robins filed to sell $11.1M2026-07-16 · SUSAN BOBULSKY filed to sell $114.5K2026-07-02 · Harlan Robins filed to sell $8.2M2026-07-01 · SUSAN BOBULSKY filed to sell $10.4K2026-07-01 · FRANCIS LO filed to sell $4.3M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ADPT: institutional holders (13F)

13F holdings, latest reported quarter
VIKING GLOBAL INVESTORS LP
29,993,708 sh
$643.4M
BlackRock, Inc.
15,139,159 sh
$324.7M
VANGUARD CAPITAL MANAGEMENT LLC
6,403,587 sh
$137.4M
WELLINGTON MANAGEMENT GROUP LLP
5,911,366 sh
$126.8M
VANGUARD PORTFOLIO MANAGEMENT LLC
5,476,231 sh
$117.5M

Congress trades in ADPT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ADPT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
SUSAN BOBULSKY
Filed 2026-10-06
$192.3K
JULIE RUBINSTEIN
Filed 2026-10-01
$11.0M
FRANCIS LO
Filed 2026-09-16
$3.8M
SUSAN BOBULSKY
Filed 2026-09-15
$29.6K
KATHERINE E OWEN
Filed 2026-08-26
$250.0K

ADPT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Genomic Advancements ETF
$1.1M position · as of 2026-06-30
4.0%
ALGER SMALL CAP FOCUS FUND
$33.7M position · as of 2026-07-31
4.0%
Lord Abbett Micro-Cap Growth Fund
$5.6M position · as of 2026-07-31
2.6%
Wasatch Ultra Growth Fund
$12.0M position · as of 2026-06-30
2.6%
ARK Genomic Revolution ETF
$40.1M position · as of 2026-07-31
2.6%
ALGER SMALL CAP GROWTH FUND
$5.0M position · as of 2026-07-31
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.1M
$39.6M
$5.0M
-73%
+25%
2024
$5.0M
$8.4M
$2.4M
-90%
-7%
2023
$8.9M
$2.7M
$4.3M
-92%
-6%
2022
$8.9M
-$1.1M
$4.3M
-87%
-10%
2021
$8.8M
-$6.2M
$5.9M
-53%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $60.4M sold by insiders over 180 days, 160 funds added last quarter, $63.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ADPT financials

Revenue growth
+54.8%
XBRL, annual
Net margin
-21.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$308.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-20.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$24.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-39.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-11.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-7.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$4.2B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-0.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$277.0M$179.0M$170.3M$185.3M
Operating income-$57.1M-$162.5M-$227.0M-$200.2M
Net income-$59.5M-$159.5M-$225.2M-$200.2M
EPS (diluted)-0.39-1.08-1.56-1.40
Operating cash flow-$46.0M-$95.2M-$156.3M-$183.9M
Cash$70.5M$47.9M$65.1M$90.0M
Long-term debt$126.6M$132.4M$130.7M$125.4M
SEC XBRL, fiscal years, as known on 2026-10-27

ADPT Stock Sonar score 6/7 axes

Find similar shapesCompare

ADPT ranks highest on financial health (99th percentile) and institutional and government (84th), and lowest on insider conviction (2nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
72
Inputs
  • Return on equity-39.6% · 61 pct, sector of 545
  • Return on assets-11.2% · 73 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-7.8% · 81 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Growth
78
Inputs
  • Revenue growth, YoY+54.8% · 78 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
2
Inputs
  • Net Form 4 buying (codes P and S), 180d-$50.6M · 4 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
84
Inputs
  • Funds adding, latest quarter160 · 84 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
68
Inputs
  • Short interest, % of float+9.4% · 41 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+2.1% · 95 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ADPT filings, in plain words

Are Adaptive Biotechnologies insiders buying or selling ADPT?

In the 180 days to 2026-10-27, Adaptive Biotechnologies insiders were net sellers, a net $60.4M across purchases and sales reported on Form 4, by 11 sellers.

Are there planned insider sales of ADPT?

Yes. 15 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $63.6M of stock; the latest, by SUSAN BOBULSKY, was filed 2026-10-06.

Read the full summary

In the 180 days to 2026-10-27, Adaptive Biotechnologies insiders were net sellers of ADPT, a net $60.4M across purchases and sales reported on Form 4 by 11 sellers. 54% of the 69 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 15 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $63.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies